1994 saw her as Head of the Department of Transplantation Immunology at the CLB, in Amsterdam, and in 1999 she became Head of the department of the Immunology of
the Laboratory of Vaccine Research of the National Institute of Public Health and Environmental Protection (RIVM), in Bilthoven, where her research activities focused on defining immunological correlates of protection on the T and B cell level after natural infection and vaccination.
Not exact matches
The long - term persistence
of CD8αα + T cells where initial infection occurs may explain why patients have asymptomatic recurrences
of genital herpes because these cells constantly recognize and eliminate the virus, according to Jia Zhu, Ph.D., corresponding author,
research assistant professor in
Laboratory Medicine at the University
of Washington and an affiliate investigator in the Fred Hutch
Vaccine and Infectious Disease Division.
«The best explanation for what we are seeing is that frequently, after exposure to HIV, a few cells in the genital tract are infected, without establishment
of a systemic infection,» says senior investigator Eric Hunter, PhD, professor
of pathology and
laboratory medicine at Emory University School
of Medicine, Emory
Vaccine Center, and Yerkes National Primate
Research Center.
This could lead to new HIV
vaccine strategies that are able to stimulate the rare precursors
of these protective antibodies,» says Professor Lynn Morris, from the National Health
Laboratory Service in the Wits School
of Pathology who leads the
research team at the NICD.
A team
of scientists at the
Vaccine Research Center (VRC)
of the National Institute
of Allergy and Infectious Diseases, part
of NIH, created VRC07 - αCD3 under the leadership
of VRC Director John R. Mascola, M.D.; former VRC Director Gary J. Nabel, M.D., Ph.D.; and Richard A. Koup, M.D., VRC deputy director and chief
of its immunology
laboratory.
«An RSV
vaccine with this M2 - 2 deletion could tip the balance toward a better immune response, which is what we predicted based on earlier
laboratory studies,» says study leader Ruth A. Karron, MD, director
of the Center for Immunization
Research and a professor in the Department
of International Health at the Bloomberg School.
The
Laboratory of Molecular Microbiology and Biotechnology is part
of this Department, and its
research focuses on microbial genetics, host - pathogen interaction, recombinant
vaccines and
vaccine immunology.
Other researchers on this project are Samina Alam,
research associate, Penn State; Brian Bowser, PPD Vaccines and Biologics Laboratory; Mohd Israr, Feinstein Institute for Medical Research; and Michael Conway, Central Michigan University College of M
research associate, Penn State; Brian Bowser, PPD
Vaccines and Biologics
Laboratory; Mohd Israr, Feinstein Institute for Medical
Research; and Michael Conway, Central Michigan University College of M
Research; and Michael Conway, Central Michigan University College
of Medicine.
Today, about 70 percent
of the
research under way in Dr. Steinman's
laboratory at Rockefeller focuses on designing a
vaccine against HIV.
He is currently an Assistant Professor and the Principal Investigator
of the Viral Dynamics
laboratory at the Center for Virology and
Vaccine Research at the BIDMC.
In addition to preventive
vaccines, such as Gardasil and Cervarix,
laboratory research and several human clinical trials are focused on the development
of therapeutic HPV
vaccines.
He is the recipient
of several awards and honors, including the NIH Director's Translational
Research Award and the
Vaccine Industry Association Outstanding Academic
Research Laboratory.
The Weiner
laboratory represents one
of the pioneering
research teams in the field
of DNA
vaccines and immune therapies.
First, in 2001, CRI formed a partnership with the Ludwig Institute for Cancer
Research to develop the Cancer
Vaccine Collaborative (CVC)-- a centralized, academic, global network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer vaccine production faci
Vaccine Collaborative (CVC)-- a centralized, academic, global network
of clinical trial sites, immune monitoring
laboratories, and clinic - grade, GMP cancer
vaccine production faci
vaccine production facilities.
The
Laboratory of Microbial Immunity is part
of this Department, and its
research focuses on host - pathogen interaction, recombinant
vaccines and
vaccine immunology.